TEST DETAILS

CYP19A1 Variation Test

Decode Your Estrogen Risk: Avoid gyno and bloat by knowing what your genes are telling you

risk awarenessestrogen levels(T/E) ratio influence

What gene we test?

CYP19A1 (rs2414096)

Scientific name

Cytochrome P450 family 19 subfamily A member 1

What does it do?

CYP19A1 encodes aromatase, the enzyme responsible for converting testosterone and androstenedione into estrogens (estradiol and estrone). This process is crucial in maintaining hormonal balance, especially in men using testosterone or anabolic steroids, where estrogenic side effects (like gynecomastia, water retention, and fat gain) are common concerns.

Variants overview

G (High-Activity level) - May convert more testosterone to estrogen; higher T-level tolerance
A (Low-Activity level) - May convert less testosterone to estrogen; lower T-level tolerance

Variant Risk Wheel

Detailed Variant Information

G (High-activity level) Variant

Frequency

~36.8% (Caucasian)

Effect

G allele is associated with higher aromatase activity → more testosterone is converted to estrogen.

Simple explanation

Individuals with high aromatase activity genotypes may convert more testosterone to estrogen, increasing the risk of gynecomastia, water retention, and fat gain.

What this means

Individuals with high aromatase activity genotypes may convert more testosterone to estrogen, increasing the risk of gynecomastia, water retention, and fat gain. They may need to monitor estrogenic side effects and consider strategies to manage aromatization under clinical guidance.

A (Low-activity level) Variant

Frequency

varies by population

Effect

A allele is linked to lower aromatase activity → less estrogen production.

Simple explanation

Those with low activity genotypes may be less prone to estrogenic side effects and may tolerate higher testosterone levels better.

What this means

Those with low activity genotypes may be less prone to estrogenic effects and may tolerate higher testosterone levels better, but individual responses vary and clinical context matters.

Included in panels

Starter Panel, Core Panel, Complete Panel